SKIN CANCERS

<div>Though Nivolumab (Opdivo) and ipilimumab (Yervoy) have demonstrated considerable success in the field of metastatic melanoma as both single agents and in combination, questions remain regarding sequencing the agents and the high toxicities that often occur when the 2 immunotherapies are used together.<br /> &nbsp;</div>

Melanoma research is rapidly advancing, explains Jedd D. Wolchok, MD, PhD, particularly with immunotherapy.<br /> <br /> &nbsp;

Today, the field of melanoma is virtually unrecognizable from what it was not that long ago.

Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD